Premium
Clofibric acid: a potential therapeutic agent in AML and MDS
Author(s) -
Fenton S. L.,
Drayson M. T.,
Hewison M.,
Vickers E.,
Brown G.,
Bunce C. M.
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1999.01355.x
Subject(s) - clofibric acid , medicine , retinoic acid , myeloid leukaemia , differentiation therapy , myeloid , cancer research , myelodysplastic syndromes , tretinoin , chemotherapy , oncology , acute promyelocytic leukemia , pharmacology , immunology , chemistry , bone marrow , biochemistry , gene
Differentiation therapy using retinoic acids (RAs) or 1α25‐dihydroxyvitamin D 3 (D 3 ) is an attractive alternative to chemotherapy in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). However, with the exception of RA therapy for acute promyelocytic leukaemia (APL), RAs and D 3 are not potent enough at doses that can be tolerated by patients. We demonstrate that clofibric acid (CA) enhances the response of HL60 cells to all‐ trans RA and D 3 . Our findings and those of others in the field lead us to suggest that combination therapy using all‐ trans RA and CA should be considered as potential therapy for AML and MDS.